Boardroom Alpha
Meeting calendar
SGI · Annual meeting · Wednesday, May 13, 2026

Somnigroup International Inc

8 nominees · 4 ballot items.

Four proposals: (1) Elect eight directors for one-year terms; (2) Ratify Ernst & Young LLP as independent auditors for 2026; (3) Advisory (non-binding) approval of the compensation of the Named Executive Officers (say-on-pay); and (4) Approve an amendment to the Certificate of Incorporation to increase authorized common shares to 1,000,000,000.

Market cap
$15.3B
1Y TSR
+4.4%
Board grade
B
Record date
Mar 16, 2026
Filing
DEF 14A
Meeting concluded · May 13, 2026

Follow how the vote landed and what changed on Somnigroup International Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot4

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect eight directors (Christopher T. Cook, Evelyn S. Dilsaver, Simon John Dyer, Cathy Rogers Gates, Meredith Siegfried Madden, Richard W. Neu, Peter R. Sachse and Scott L. Thompson) to serve one-year terms until the 2027 annual meeting or until successors are duly elected and qualified.

  2. 2

    Ratification of Independent Auditors

    ManagementBoard: FOR

    Ratify the appointment of Ernst & Young LLP as Somnigroup's independent auditors for the year ending December 31, 2026.

  3. 3

    Advisory Vote to Approve the Compensation of Our Named Executive Officers

    ManagementBoard: FOR

    Non-binding, advisory 'say-on-pay' vote to approve the compensation of the Company's Named Executive Officers as disclosed in the proxy materials.

    More detail

    This advisory proposal asks stockholders to approve, on a non-binding basis, the compensation paid to the Company's Named Executive Officers as described in the proxy statement, including the Compensation Discussion and Analysis, compensation tables and narrative. Management seeks this vote to validate its executive pay philosophy—emphasizing pay-for-performance, a mix of short-term and long-term incentives, and substantial equity-based awards tied to adjusted EPS, adjusted EBITDA and strategic initiatives—and to demonstrate alignment between management and stockholder interests. The Board and the Human Resources/Capital and Talent Committee present the proposal as part of standard governance practice and point to robust stockholder engagement (outreach to holders representing a large percentage of shares outstanding) and a prior say-on-pay approval above 98% as evidence of strong support. The Company highlights features intended to limit excessive risk-taking (stock ownership guidelines, clawback policy, no repricing without stockholder approval, capped maximum payouts) and explains specific program design choices made after investor feedback, including 50/50 PRSU/RSU LTIP mix and performance metrics selection. The advisory nature means the vote does not change compensation contracts but will inform the Compensation Committee's decisions going forward; management explicitly commits to considering the outcome in future program design. Key governance context includes the Compensation Committee's use of an independent compensation consultant and disclosure of pay outcomes (including one-time awards and transaction bonuses) that may affect votes; the proxy also explains recent special awards (e.g., CEO option award and transaction bonus) that investors may scrutinize. Stockholders should weigh alignment mechanisms and performance outcomes (e.g., 2025 adjusted EPS/EBITDA results and PRSU payouts) against dilution and exceptional awards when evaluating the proposal. The Board's rationale for recommending FOR emphasizes alignment with long-term strategy, retention and post-acquisition integration (e.g., Mattress Firm), and the Committee's responsiveness to investor feedback.

  4. 4

    Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock

    ManagementBoard: FOR

    Approve an amendment to Article IV of the Certificate of Incorporation to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (total authorized shares of all classes to 1,010,000,000).

    More detail

    This management proposal would amend the Company's Certificate of Incorporation to increase authorized common stock from 500 million to 1 billion shares (raising total authorized to 1,010,000,000 including preferred). Management frames the amendment as a precautionary measure to provide flexibility for future corporate needs—financing, strategic transactions, stock splits, employee equity programs, or other general corporate purposes—without the delay and cost of reconvening stockholders for another vote. The Board emphasizes there are no definite plans to issue the newly authorized shares immediately and discloses the current fully diluted share count (~221.4 million as of March 2, 2026), noting about 216 million shares currently unissued and unreserved. From a governance perspective, increasing authorized shares can materially dilute existing shareholders if used aggressively; management acknowledges this risk and states no present intent to use the increase for anti-takeover purposes, although the additional shares could be used in ways that make control changes more difficult. The proposal requires affirmative vote of a majority of outstanding shares—thus it is a high-threshold, shareholder-level authorization—and the Board contends approval better positions the Company to respond quickly to market opportunities post-acquisition integration (e.g., Mattress Firm). Investors should weigh the utility of ready access to authorized shares for strategic flexibility against potential dilution, and consider whether additional safeguards (e.g., pre-approval for large issuances, shareholder approval for material M&A financings) are warranted. The Board’s recommendation cites the benefits of agility and preparedness in a post-acquisition company and frames the amendment as a prudent governance step to preserve optionality for the Board and management.

Director elections

Nominees on the ballot8

Independent
Tenure on this board
16.6 yrs
Also a director at
Healthequity Inc (HQY)Quidelortho Corp (QDEL)Pacs Group Inc (PACS)
Cathy Rogers Gates
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
10.8 yrs
Also a director at
Huntington Bancshares Inc (HBAN)
Ownership

Top institutional holders10

Latest 13F quarter
1FMR LLC9.2%19,372,289$1.4B
2BlackRock, Inc.6.0%12,593,539$931M
3Select Equity Group, L.P.4.4%9,273,908$686M
4VANGUARD CAPITAL MANAGEMENT LLC4.3%9,078,255$671M
5Linonia Partnership LP4.2%8,782,011$649M
6VANGUARD PORTFOLIO MANAGEMENT LLC4.0%8,438,240$624M
7WINDACRE PARTNERSHIP LLC3.9%8,222,760$608M
8STATE STREET CORP3.3%6,890,473$509M
9BlackRock, Inc.2.9%6,092,016$450M
10BROWNING WEST LP2.8%5,896,706$436M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Somnigroup International Inc 2026 annual meeting?
Somnigroup International Inc (SGI) holds its 2026 annual shareholder meeting on Wednesday, May 13, 2026.
What is the record date for the Somnigroup International Inc 2026 meeting?
The record date for the Somnigroup International Inc 2026 meeting is Monday, March 16, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Somnigroup International Inc's 2026 meeting?
The board is presenting 8 director nominees at the Somnigroup International Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Somnigroup International Inc 2026 meeting?
Shareholders will vote on 4 proposals at the Somnigroup International Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer